Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mouse Models of Cancer Study02:43

Mouse Models of Cancer Study

5.5K
Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
5.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Author Correction: The foundations of immune checkpoint blockade and the ipilimumab approval decennial.

Nature reviews. Drug discovery·2022
Same author

The foundations of immune checkpoint blockade and the ipilimumab approval decennial.

Nature reviews. Drug discovery·2021
See all related articles

Related Experiment Video

Updated: May 26, 2025

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System
06:23

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

Published on: January 12, 2017

14.6K

The Problem with Syngeneic Mouse Tumor Models.

Nils Lonberg1

  • 1Canaan Partners, Menlo Park, California.

Cancer Immunology Research
|February 25, 2025
PubMed
Summary

Syngeneic mouse models, foundational for cancer immunotherapies, fail to mimic human solid tumors. Understanding these differences is key to improving cancer drug development and reducing costly clinical trial failures.

Area of Science:

  • Oncology
  • Immunology
  • Translational Medicine

Background:

  • Syngeneic mouse tumor models are widely used for cancer immunotherapy research.
  • These models often fail to accurately represent human solid tumors and their immune interactions.
  • This discrepancy contributes to the high failure rate of clinical trials.

Purpose of the Study:

  • To highlight the limitations of current syngeneic mouse models in cancer immunotherapy research.
  • To propose a shift in perspective, viewing these models as in vivo assays rather than direct disease models.
  • To suggest strategies for improving the translatability of preclinical findings to human patients.

Main Methods:

  • Comparative analysis of immune responses in syngeneic mouse models versus human solid tumors.

More Related Videos

Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer
06:20

Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer

Published on: October 4, 2022

2.6K
Modeling Primary Bone Tumors and Bone Metastasis with Solid Tumor Graft Implantation into Bone
06:53

Modeling Primary Bone Tumors and Bone Metastasis with Solid Tumor Graft Implantation into Bone

Published on: September 9, 2020

2.7K

Related Experiment Videos

Last Updated: May 26, 2025

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System
06:23

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

Published on: January 12, 2017

14.6K
Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer
06:20

Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer

Published on: October 4, 2022

2.6K
Modeling Primary Bone Tumors and Bone Metastasis with Solid Tumor Graft Implantation into Bone
06:53

Modeling Primary Bone Tumors and Bone Metastasis with Solid Tumor Graft Implantation into Bone

Published on: September 9, 2020

2.7K
  • Evaluation of the immune system's stage in transplanted tumor cells versus patient tumors.
  • Discussion of the implications for preclinical drug development.

    • Main Results:

    • Syngeneic models represent an early immune response stage, unlike the mature stage in human patients.
    • The lack of faithful recapitulation leads to poor translatability and costly clinical trial failures.
    • Existing models may be more valuable for understanding immunotherapy mechanisms than for predicting clinical efficacy.

    Conclusions:

    • Rethinking the application of syngeneic models is crucial for advancing cancer immunotherapy.
    • Treating these models as in vivo assays can refine drug development pathways.
    • Further research into model-human differences will accelerate the discovery of effective immunotherapies.